Lanadelumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), DMC (Denmark) and HAS (France), among others, recommended or restricted lanadelumab, while AOTMIT (Poland) and CONITEC (Brazil) did not recommend it.
Assessment has run over 6.9 years, from 19 Dec 2018 at AWMSG (Wales) to 6 Nov 2025 at HIRA (South Korea).
TLV (Sweden) changed its position: not recommended on 26 Nov 2020, restricted by 18 Jun 2024, after a resubmission.
Every one of the eight highest-volume agencies in this archive has a record for lanadelumab.
The file is active: 10 of 23 records date from 2023 or later.
3 distinct indication wordings are recorded for lanadelumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
3 of these 23 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess lanadelumab, on 19 Dec 2018; HIRA (South Korea) did not open a file until 6 Nov 2025 — a wide spread of 6.9 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 7 years in total.
5 of the 15 agencies here assessed lanadelumab more than once, HAS (France) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
lanadelumab has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for lanadelumab reads 10 recommended, 4 not recommended, 4 restricted and 3 no benefit, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 5 Nov 2025 | Re-assessment of SMR and ASMR | SMR substantial · ASMR IV | source |
| CONITEC (Brazil) | 29 May 2025 | Tratamento da profilaxia de crises de angioedema hereditário tipo I/II, em que o paciente apresentou falha ou tem contra… | not incorporated | source |
| CIPM (Spain) | 18 Dec 2024 | Indicación terapéutica autorizada: TAKHZYRO está indicado para la prevención rutinaria de las crisis recurrentes de angi… | financed by the SNS · art. 92 b, c | source |
| PHARMAC (New Zealand) | 6 Nov 2024 | Routine prevention of recurrent attacks of hereditary angioedema | PTAC advice: High | source |
| PBAC (Australia) | 2020 | Hereditary angioedema (HAE) | The PBAC deferred making a recommendation for the listing of lanadelumab for routine (long… | source |
18 further decisions for lanadelumab, across 13 agencies, are not shown here. They include the most recent record on file, 6 Nov 2025 from HIRA (South Korea); its outcome is in the subscriber dataset. They link to 15 further source documents.
Related molecules
- exagamglogene autotemcel — same ATC class B06A — Other hematological agents
- icatibant — same ATC class B06A — Other hematological agents
- berotralstat — same ATC class B06A — Other hematological agents
- garadacimab — same ATC class B06A — Other hematological agents
- conestat alfa — same ATC class B06A — Other hematological agents
- donidalorsen — same ATC class B06A — Other hematological agents
Coverage: 23 decisions for lanadelumab from 15 agencies, 2018 to 2025. Data to 7 Sep 2026. ATC class B06A — Other hematological agents. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.